Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Overall Survival (OS)

OS is defined as as the time between the date of randomization and the date of death.

Time frame: up to 106.6 months

The Safety and Tolerability of Nivolumab and Ipilimumab Measured by the Incidence of Adverse Events

the safety and tolerability of Nivolumab and Ipilimumab was measured by the incidence of adverse events

Time frame: reported between first dose and 30 days after last dose of study therapy

The Safety and Tolerability of Nivolumab and Ipilimumab Measured by the Incidence of Serious Adverse Events

The Safety and Tolerability of nivolumab and ipilimumab was measured by the incidence of serious adverse events

Time frame: reported between the first dose and 30 days after last dose of study therapy

the Safety and Tolerability of Nivolumab and Ipilimumab Measured by the Incidence of Deaths

the safety and tolerability of Nivolumab and Ipilimumab was measured by the incidence of Deaths

Time frame: reported between first dose and 30 to 100 days after last dose of study therapy

The Safety and Tolerability of Nivolumab and Ipilimumab Measured by the Incidence of Laboratory Abnormalities

The Safety and Tolerability of Nivolumab and Ipilimumab measured by the incidence of Laboratory abnormalities.

Time frame: reported after first dose and within 30 days of last dose of the study therapy